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Background. Choline positron emission tomography (PET)/computed tomography (CT) is a currently used diagnostic tool in restag-
ing prostate cancer (PCa) patients with increasing prostate-speciﬁc antigen (PSA) after either radical prostatectomy (RP) and/or
external-beam radiation therapy (EBRT).
Purpose. To assess the accuracy of 11C-Choline PET/CT (Chol-PET/CT) for the detection of recurrences after biochemical failure
(BF) in PCa patients treated with RP, EBRT or both, and to analyse its role as a guide for tailored therapeutic strategies.
Methods. From March 2011 to February 2013, 44 studies 11C-Choline PET/CT were realized in PCa patients (p) with BF. All patients
were enrolled in Gregorio Maran˜on Hospital (Madrid). Median age was 67.6 years [55–81]; median PSA before BF was 7.9ng/mL
[0.38–87]. Conventional imaging negative tests (CT, bone scan) and BF data make the indication to determinate the location of
macroscopic/metabolic relapse.
Results. Median BF free-survival was 30.5 months [1–134]. The diagnostic accuracy of choline PET/CT in detecting sites of PCa
relapse was 75%. 77% of them had been treated with initial RP and 10 patients (p) with primary EBRT. 22p showed metastases (68%
nodal recurrences), 9p local recurrence and 3p had a second primary tumor. Salvage treatment options were lymphadenectomy
(8p), androgen deprivation (5p), observation (4p), cryotherapy (4p) or chemotherapy (1p).
Conclusion. 11C-Choline PET/CT is a useful tool in locating persistent or recurrence disease after BF when other imaging tests are
negative. This technique could change the management approach for individualised treatment of recurrence.
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